STAT+: Lilly’s Ajax acquisition may have been worth it

Article excerpt

Pfizer's Bicillin shortage left an Arizona pregnant woman unable to get timely syphilis treatment, highlighting a critical supply crisis for this injectable penicillin. Meanwhile, the FDA approved Sanofi's diabetes drug Tzield following an unusually contentious review, and the Trump administration moved to close a Medicare negotiation loophole. The piece examines whether Eli Lilly's Ajax acquisition proved worthwhile amid these broader shifts in drug access and regulation.